FDA
-
-
-
-
-
-
-
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
-
-
-
-
-
-
-
Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
-
-
-
-
-
-
-
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program
-
-
-
-
-
-
-
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy
-
-
-
-
-
-
-
Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)
-
-
-
-
-
-
-
Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis
-
334,272 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


